Keytruda Provides Disease Control in Patients with Metastatic Castration-resistant Prostate Cancer, Trial Shows

Keytruda Provides Disease Control in Patients with Metastatic Castration-resistant Prostate Cancer, Trial Shows
Treatment with Keytruda (pembrolizumab) provides anti-tumor activity and disease control in patients with metastatic castration-resistant prostate cancer (mCRPC), Merck’s large-scale Phase 2 study shows. The company presented the study, “KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC),” at the American Society of Clinical Oncology (ASCO) Annual Meeting, on Monday as part of the

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *